In the past decade, significant progress has been made toward using immunotherapy for the treatment of cancer. The process aims to stimulate (or in some cases restore) a patient’s immune system to recognize and destroy cancer cells. Several immunotherapies have been approved by the FDA and two have shown remarkable clinical results. Yet each has limitations.
For this presentation, immunotherapy researcher, Eric Lutz, will discuss two new personalized immunotherapeutic approaches that aim to address shortcomings of recently approved cancer immunotherapies.
Free and open to the public, Lutz’s keynote kicks off the 9th Annual Natural Sciences Networking event at Albright College.
Eric Lutz, Ph.D. ’00
For the past 18 years, Albright biochemistry graduate Eric Lutz, Ph.D. ’00 has been involved in tumor immunotherapy-focused research. Currently director of research at WindMIL Therapeutics (Baltimore, Md.), Lutz is focused on developing a novel form of adoptive cellular therapy named Marrow-infiltrating Lymphocytes (MILs) for the treatment of both solid and hematologic malignancies. Prior to joining WindMIL in 2016, he focused on the development of immunotherapy for pancreatic cancer as an assistant professor in the Johns Hopkins Gastrointestinal Oncology Division. After graduating from Albright, Lutz earned a doctorate in immunology from the Johns Hopkins School of Medicine and completed a postdoctoral fellowship in tumor immunology.
